Shares of Preveceutical Medical Inc (CNSX: PREV) are surging months after the company-touted milestones achieved on research and development programs well as plans to become a global preventive healthcare company. A recent spike in share price and market activity also comes on the health sciences company announcing a default judgment against Esso’s Corporate Services Inc.
CNSX: PREV Catalysts and Share Price Analysis
Investors’ confidence on the stock also appears to have inched higher on PreveCeutical announcing preliminary screening results for peptides derived from Blue Scorpion. The health sciences company is also exploring strategic partnerships for the development of its Sol-Gel system as part of its growth strategy.
Price action indicates the stock might have a reached a bottom and due for a bounce back from all-time lows. A 100%-plus spike from all-time lows indicates the upward momentum is gaining pace and that the stock is due for a correction on the upside.
A spike to the $0.05 level has opened the door for PreveCeutical to make a run for the $0.07 level as part of the emerging uptrend. A surge followed by a close above the $0.07 level should give bulls every reason to continue pushing the stock higher as part of the emerging uptrend.
For PreveCeutical to turn bullish after imploding in 2018, it needs to rally and stabilize above the $0.11 technical level. Conversely, the stock remains bearish below the $0.07 resistance level given the underlying long-term bear trend.
PreveCeutical is a health sciences company specializing in the development of innovative options for preventive and curative therapies. The company is currently working on five research and development programs as it seeks to become a leader in preventive health sciences.
Why is PreveCeutical Bottoming Out?
Shares of PreveCeutical have started bottoming out on investors reacting to improving underlying fundamentals. In January, the company confirmed it was pursuing strategic partnerships with pharmaceutical and biotechnology companies.
The health sciences company is planning to leverage partnerships to accelerate the development of therapies for neurological disorders. Such alliances should also allow the company to accelerate the development of its soluble gel, Sol-Gel delivery system.
Sol-Gel is the company’s lead system for enhancing the delivery of pharmaceuticals to the central nervous system.
“Sol-gel technology has certainly shown significant promise in laboratory testing at this point. Eventually, I would like to see this proprietary technology be successfully applied to a drug which could be targeted for CNS delivery,” stated PreveCeutical Chief Science Officer, Dr. Make Jawadekar.
PreveCeutical has also achieved significant milestones on the development of its dual, gene therapy program siRNA. The company has completed the design process that involved strategic interchanging of individual nucleic acids.
The company’s research program for the development of non-addictive analgesics is also progressing well. The company has already identified five novel peptide constructs that target the receptor subtype. The peptides have already demonstrated potency in a well-accepted functional dose response assay.
Dr. Harendra Parekh commented, “We are very pleased with this promising development, as a result of numerous iterations between our peptide design and cell-based screening efforts, we have now yielded a number of constructs which discriminate between the key pain receptors in the body, and importantly, avoid activation of those purported to lead to dependence.”
Peptide Therapeutics Milestones
In March, PreveCeutical achieved yet another milestone on posting positive trial results from a preliminary screening of key peptides as part of its scorpion venom-derived peptide research program.
With the positive trial results, the health services company can now move forward and generate natural identical peptide therapeutics for therapeutic applications. PreveCeutical intends to pursue the program with a focus on activities such as peptides in cell-based brain cancer models.
PreveCeutical has already identified a lead peptide candidate capable of inhibiting critical proteins implicated in driving aggressive nature of certain brain cancers.
What Next For PreveCeutical
A PreveCeutical fine start to the second quarter looks set to persist as investors take note of the progress made on the research and development front. The company has achieved significant milestones on the development of its sol-gel delivery system, dual gene therapy program as well development of non-addictive analgesics.
The milestones achieved point to a bright future expected to trigger renewed investor interest in the stock, which should lead to a higher valuation in the market. The stock should continue to rally given that it has a lot of room to run on the upside.
We will be updating our subscribers as soon as we know more. For the latest updates on CNSX: PREV, sign up below!
Disclosure: We have no position in CNSX: PREV and have not been compensated for this article.